Transform how you analyse drug development risk
With the only transparent analysis of drug development risk at the product level.
Press Releases
Welcome to our press release archive. If you have questions about Evaluate or require data and expert insights to help support your editorial content, please see our Media Contacts.
Latest Press Releases
Evaluate Ltd. transforms pharma R&D risk assessment with launch of Product Specific PTRS
Breakthrough offering combines the power of machine learning with the transparency of Evaluate’s renowned analytical approach for the most accurate analysis of drug…
Vantage Half-Year Review 2019: Pharma and medtech mega-deals mask drop in M&A activity
The report, published today, analyses stock and market performance, M&A and the financing landscape during the first half of 2019
Innovation and unmet need drive prescription drug sales to $1.18tr by 2024: new report from Evaluate Ltd
“EvaluatePharma® World Preview 2019, Outlook to 2024” explores growth drivers, growth brakes and top industry performers.
Browse the archive
Evaluate Ltd. transforms pharma R&D risk assessment with launch of Product Specific PTRS
Breakthrough offering combines the power of machine learning with the transparency of Evaluate’s renowned analytical approach for the most accurate analysis of drug…
Vantage Half-Year Review 2019: Pharma and medtech mega-deals mask drop in M&A activity
The report, published today, analyses stock and market performance, M&A and the financing landscape during the first half of 2019
Innovation and unmet need drive prescription drug sales to $1.18tr by 2024: new report from Evaluate Ltd
“EvaluatePharma® World Preview 2019, Outlook to 2024” explores growth drivers, growth brakes and top industry performers.
The “one and done” era for orphan drugs: Evaluate predicts 12% growth, driven by new technologies, but benefits go to big pharma
Orphan drug sales reach $242bn by 2024, according to EvaluatePharma® Orphan Drug Report 2019
Biopharma in 2018: A year of contrasts as stocks and M&A slump, but venture financing and IPOs remain strong
Vantage releases annual analysis of Pharma, Biotech and Medtech performance
Uncertainty for pharma and biotech in 2019 as sector stumbles at the end of 2018
Vantage’s Annual Pharma and Biotech Preview explores what’s in store for 2019
Worldwide medtech sales forecast to reach $595 billion by 2024, with a CAGR of 5.6%, anchored by familiar players
Evaluate Ltd. releases annual “EvaluateMedtech World Preview 2018, Outlook to 2024” in conjunction with The Medtech Conference
Small drug developers continue to hold all the cards, while young device makers suffer from a shrinking pool of buyers
Vantage releases its half-year analysis of sector performance: Pharma, Biotech and Medtech Half-Year Review 2018
Worldwide Prescription Drug Sales Accelerate To $1.2 Trillion By 2024, As Unmet Need Drives Annual Compound Growth To Over 6%
Eleventh annual EvaluatePharma World Preview 2018, Outlook to 2024 report launches at BIO 2018.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.